Cytosorbents Corp Stock OTC Bulletin Board
Stocks
CTSO
US23283X1072
Advanced Medical Equipment & Technology
| Market Cap | 23.7M 20.58M 19.19M 17.63M 33.33M 2.25B 33.7M 226M 88.42M 1.13B 89M 87.05M 3.73B | P/E 2026 * |
-2.04x | P/E 2027 * | 12.6x |
|---|---|---|---|---|---|
| Enterprise Value | 23.7M 20.58M 19.19M 17.63M 33.33M 2.25B 33.7M 226M 88.42M 1.13B 89M 87.05M 3.73B | EV / Sales 2026 * |
0.62x | EV / Sales 2027 * | 0.5x |
| Free-Float |
84.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytosorbents Corp
| 1 day | -6.91% |
| Manager | Title | Age | Since |
|---|---|---|---|
Phillip Chan
CEO | Chief Executive Officer | 55 | 24/07/2008 |
Peter Mariani
DFI | Director of Finance/CFO | 62 | 14/08/2024 |
Vincent Capponi
PSD | President | 68 | 28/04/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Edward Jones
BRD | Director/Board Member | 77 | 25/07/2011 |
Phillip Chan
BRD | Director/Board Member | 55 | 01/01/2009 |
Alan Sobel
BRD | Director/Board Member | 65 | 13/11/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.91% | -.--% | - | - | 23.7M | |
| +1.67% | -0.19% | +23.36% | +4.28% | 209B | |
| +1.70% | +1.07% | -0.22% | -22.31% | 137B | |
| +0.78% | +5.50% | -21.90% | +20.47% | 130B | |
| -2.64% | +4.34% | -54.17% | -5.30% | 71.14B | |
| -0.43% | +4.94% | +13.58% | +12.73% | 51.59B | |
| +0.41% | +4.37% | -14.40% | -19.70% | 49.99B | |
| +1.10% | +0.16% | +22.32% | +11.08% | 39.31B | |
| +0.42% | +4.27% | +40.71% | +36.57% | 38.89B | |
| -0.04% | +4.40% | -21.50% | +19.85% | 32.19B | |
| Average | -0.40% | +3.19% | -1.36% | +6.41% | 84.33B | |
| Weighted average by Cap. | +0.73% | +1.42% | -0.14% | +3.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.26M 33.22M 30.98M 28.46M 53.82M 3.64B 54.41M 365M 143M 1.82B 144M 141M 6.03B | 47.12M 40.92M 38.15M 35.05M 66.28M 4.48B 67.01M 450M 176M 2.24B 177M 173M 7.42B |
| Net income | -11.74M -10.19M -9.51M -8.73M -16.51M -1.12B -16.7M -112M -43.81M -558M -44.09M -43.12M -1.85B | 2.37M 2.06M 1.92M 1.76M 3.34M 226M 3.37M 22.65M 8.85M 113M 8.91M 8.72M 374M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
